178 related articles for article (PubMed ID: 6541103)
1. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Gold HK; Fallon JT; Yasuda T; Leinbach RC; Khaw BA; Newell JB; Guerrero JL; Vislosky FM; Hoyng CF; Grossbard E
Circulation; 1984 Oct; 70(4):700-7. PubMed ID: 6541103
[TBL] [Abstract][Full Text] [Related]
2. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
[TBL] [Abstract][Full Text] [Related]
3. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
4. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
[TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue-type plasminogen activator ameliorates ischemic derangements induced by thrombotic occlusion in closed chest anesthetized dogs.
Egashira K; Kawai K; Nagano M; Sakuma A; Nakamura M; Tomoike H
J Am Coll Cardiol; 1992 Jul; 20(1):218-25. PubMed ID: 1607528
[TBL] [Abstract][Full Text] [Related]
6. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
Flameng W; Van de Werf F; Vanhaecke J; Verstraete M; Collen D
J Clin Invest; 1985 Jan; 75(1):84-90. PubMed ID: 4038406
[TBL] [Abstract][Full Text] [Related]
7. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Chen LY; Nichols WW; Saldeen TG; Mehta JL
J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
[TBL] [Abstract][Full Text] [Related]
8. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
Van de Werf F; Bergmann SR; Fox KA; de Geest H; Hoyng CF; Sobel BE; Collen D
Circulation; 1984 Mar; 69(3):605-10. PubMed ID: 6362907
[TBL] [Abstract][Full Text] [Related]
9. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
[TBL] [Abstract][Full Text] [Related]
10. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
[TBL] [Abstract][Full Text] [Related]
12. Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol.
Van de Werf F; Vanhaecke J; Jang IK; Flameng W; Collen D; De Geest H
Circulation; 1987 Apr; 75(4):830-6. PubMed ID: 3103951
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.
Tiefenbrunn AJ; Robinson AK; Kurnik PB; Ludbrook PA; Sobel BE
Circulation; 1985 Jan; 71(1):110-6. PubMed ID: 4038368
[TBL] [Abstract][Full Text] [Related]
14. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
Kopia GA; Kopaciewicz LJ; Fong KL; Crysler CS; Boyle K; Ruffolo RR
J Cardiovasc Pharmacol; 1988 Sep; 12(3):308-16. PubMed ID: 2464103
[TBL] [Abstract][Full Text] [Related]
16. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
Susawa T; Yui Y; Hattori R; Takatsu Y; Yui N; Takahashi M; Aoyama T; Murohara Y; Shirotani M; Kawai C
Jpn Circ J; 1988 Jan; 52(1):72-8. PubMed ID: 3129601
[TBL] [Abstract][Full Text] [Related]
18. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
Longridge DJ; Follenfant MJ; Maxwell MP; Ford AJ; Hughes B
Cardiovasc Res; 1990 Sep; 24(9):697-706. PubMed ID: 2121357
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
Kido H; Hayashi K; Uchida T; Watanabe M
Jpn Heart J; 1995 Jan; 36(1):61-79. PubMed ID: 7760515
[TBL] [Abstract][Full Text] [Related]
20. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
